Previous 10 | Next 10 |
Dr. Shah Has Spent Over Two Decades Leading Biological Development Teams at Biotechnology Companies and Has Deep Expertise in Protein Development and Manufacturing DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatm...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, today announced that Rick Pauls, its President and CEO will be participating at Lake Street Capital Market’s 7 th Annual Best Ideas ...
2023-08-15 15:43:02 ET DiaMedica Therapeutics Inc. (DMAC) Q2 2023 Earnings Call Transcript August 15 2023, 08:00 AM ET Company Participants Rick Pauls - President and CEO Scott Kellen - CFO Conference Call Participants Thomas Flaten - Lake Street Capital ...
2023-08-14 16:23:20 ET DiaMedica Therapeutics press release ( NASDAQ: DMAC ): Q2 GAAP EPS of -$0.16 beats by $0.02 . DiaMedica reported total cash, cash equivalents and investments of $60.7 million, current liabilities of $1.9 million and working capital of $39.3 milli...
Conference Call and Webcast August 15 at 8:00 am Eastern Time / 7:00 am Central Time Company Resumes ReMEDy2 Clinical Trial after Clinical Hold Lifted Company Completed a $37.5M “At-The-Market” Private Placement, Cash Runway Into 2026 Company Co...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its second quarter 2023 financial results will be released after the markets close on Mo...
2023-08-06 04:08:12 ET Summary DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on developing recombinant proteins to treat life-threatening diseases. Its main clinical candidate, DM199, is undergoing evaluation in a Phase 2/3 study for the treatment of...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, today announced the company will be attending the 2023 AAN Summer Conference on July 28-29, at the Minneapolis Hyatt Regency. This year...
2023-06-27 02:52:23 ET Clinical stage biopharmaceutical company, DiaMedica Therapeutics ( NASDAQ: DMAC ) rose 4.5% to $4.40 on Monday late hours. The company filed Form 4 that shows executives and directors buying company stock. Director Randall Michael Giuf...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced the closing of its previously announced $37.5 million private placement to accredited investors. The Compan...
News, Short Squeeze, Breakout and More Instantly...
DiaMedica Therapeutics Inc. Company Name:
DMAC Stock Symbol:
NASDAQ Market:
DiaMedica Therapeutics Inc. Website:
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced the closing of its previously announced $11.8 million private placement to accredited investors. The Company sold approximatel...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 73.0% to $0.4585 on volume of 640,087,036 shares Ocean Power Technologies Inc. (OPTT) rose 34.9% to $0.1812 on volume of 396,326,565 shares NVIDIA Corporation (NVDA) rose 0.2% to $1...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it has entered into definitive agreements to sell its common shares in a private placement with accredited investors. Th...